Compare Regeneron Pharmaceuticals Inc (REGN) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Sony Group Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Sony Group Corp trades at $20.89 (market cap $124.97B). The key difference: Sony Group Corp is the larger of the two by market cap, and Sony Group Corp pays the higher dividend (0.75%). Which is the better fit depends on your goals.
| REGN | SONY | |
|---|---|---|
Market Cap | $70.79B | $124.97B |
Sector | Health | Technology |
52-Week High | $812.27 | $30.26 |
52-Week Low | $545.46 | $19.32 |
Enterprise Value | $64.74B | $121.48B |
Dividend Yield | 0.56% | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Sony trades at $21.02, down 0.47% on the day. The stock shows a bullish technical signal with strong moving average alignment, though oscillators are neutral. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Revenue for 2025 was $12.96 trillion with a net income of $1.14 trillion, though 2026 projections indicate a net loss. Analyst sentiment is positive with 11 buy ratings and no sell recommendations.
The outlook for Sony is mixed; strong cash flow and a solid balance sheet support growth in entertainment and AI investments, but the shift away from physical media and projected 2026 losses pose risks. Investor sentiment remains cautiously optimistic given the bullish analyst consensus and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
